The company announced yesterday the Oxford coronavirus vaccine is 100% effective at preventing serious disease (Picture: SWNS)
The US has raised concerns about the latest data from AstraZeneca regarding the effectiveness of its coronavirus vaccine.
Results from a major trial in the US published yesterday showed the jab is 100% effective at preventing serious disease, and 79% effective against symptomatic Covid-19.
It was hoped the results could rebuild public confidence in the Oxford AstraZeneca vaccine after a number of countries temporarily suspended use of the injection over unproven fears it could cause blood clots.
But federal officials in the US said last night they were ‘concerned’ the information provided by the British drug manufacturer may have been out of date.
The National Institute of Allergy and Infectious Diseases said in a statement: ‘The Data and Safety Monitoring Board (DSMB) expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data.
‘We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.’
AstraZeneca has not yet responded to the the statement.
The latest trial gave 32,000 volunteers in the US, Chile and Peru two doses, four weeks apart.
The AstraZeneca Oxford jab has seen public confidence drop over unproven fears it could cause blood clots (Picture: AFP via Getty Images)
A fifth of those involved were over 65 – the age group most at risk of serious illness.
A total of 141 cases of symptomatic Covid-19 were reported among all the trialists but none had to be taken to hospital.
Among the over 65s, there was found to be 80% protection against developing Covid.
The degree of effectiveness for the jab was even higher than observed in the Oxford-led clinical trials, which led to it being given approval in the UK.
Andrew Pollard, the lead investigator of the Oxford University trial of the vaccine, said: ‘These results are great news as they show the remarkable efficacy of the vaccine in a new population and are consistent with the results from Oxford-led trials.
‘We can expect strong impact against Covid-19 across all ages and for people of all different backgrounds from widespread us of the vaccine.’
Most countries have now resumed use of the vaccine after a European Medicines Agency review concluded it did not raise the overall risk of blood clots.
AstraZeneca is now expected to submit data to the US Food and Drug Administration and seek emergency approval for its use in America.
Get in touch with our news team by emailing us at [email protected].
For more stories like this, check our news page.